May 11, 2018
TOKYO, JAPAN - May 11, 2018 - Terumo Corporation (TSE: 4543) today announced that it has appointed an associate of MicroVention, Inc., a U.S.-based subsidiary of Terumo, as the fifth "Terumo Fellow." Terumo instituted the Terumo Fellow program to recognize associates who have made outstanding contributions leading to innovation in medical settings, and in the technology, research, and clinical development of the Terumo Group. Terumo created the program and appointed four individuals as Terumo Fellows in 2016.
The new appointed person is Gregory M. Cruise, Ph.D., Senior Director, Materials Development, MicroVention, Inc. His work to develop innovative coils for intracerebral aneurysms has been recognized as having had a major positive impact not only on the MicroVention business, but also on the lives of patients themselves. In addition to this, he has been providing a great value to cancer patients with unique microbeads technologies.
Terumo has established its Global Vision as "Innovating at the Speed of Life," with the aim of achieving further innovation for the benefit of medical professionals and the lives of patients. Terumo will continue to pursue research and development that will produce innovation that benefits healthcare throughout the world.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the health care market, and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.